Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including metabolic disease, oncology, CNS, inflammation and cardiovascular disease.
Plexxikon's unique discovery approach, combined with an experienced management and scientific team, a broad network of scientific and clinical experts, and creative partnering, have been key drivers of the company's success since it began operations in 2001.
With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. This systematic, cost-efficient approach allows Plexxikon to leverage its chemistry investment in any one drug target for other targets within that family. This strategy has resulted in a comprehensive portfolio and pipeline of opportunities for both its internal and partnered programs. – less–ZoomInfo